Document is current
Any future updates will be listed below
-
Authors
Jamnik, Adam A. https://orcid.org/0000-0002-5370-5958
Datcu, Anne-Marie https://orcid.org/0000-0002-5711-5277
Lachmann, Emily https://orcid.org/0000-0001-7293-2438
Rathjen, Karl https://orcid.org/0000-0003-3747-7593
Johnson, Megan https://orcid.org/0000-0002-5968-9469
Thornberg, David https://orcid.org/0000-0002-6876-0458
Jo, Chan-Hee https://orcid.org/0000-0003-2159-2095
Ramo, Brandon https://orcid.org/0000-0003-1445-230X
- License Information
-
More Information
Article History
Received: 10 March 2025
Accepted: 12 June 2025
First Online: 3 July 2025
Declarations
:
: Dr. Adam A Jamnik, Ms. Anne-Marie Datcu, Ms. Emily Lachmann, Mr. David Thornberg, Dr. Chan-Hee Jo, and Dr. Brandon Ramo have no relevant financial or non-financial interest to disclose. Dr. Karl Rathjen has no relevant financial or non-financial interests to disclose related to this work, however, he holds stocks/stock options with Mati Therapeutics. Dr. Megan Johnson has no relevant financial or non-financial interests to disclose related to this work, however, she is a consultant/advisor for Depuy/Globus/NuVasive.
: IRB approval was received before the study began. Participants were prospectively enrolled and informed consent was obtained prior to initiation (IRB #022011-127).
